


\begin{enumerate}
	\item INNOVATION, IMITATION and Market Structure in Pharmaceuticals \cite{key400}
	\item Strategies drug DISCOVERY from random GENERATED libraries to rational DESIGN \cite{key500}
	\item Movement from large MAXIMUM DIVERSE libraries to SMALL “drug-like” libraries. \cite{key500}
\end{enumerate}

\section{Pharmaceutical Immuno-Oncology Portfolio Object}

\begin{table}
	\caption{Mono-Clonal Anti-Bodies for the Immuno-Oncology Portfolio \cite{key8001} }
	\begin{tabular}{r|p{4cm}|l}
		Compound & Company & Comment \\
		\hline
		Revlimid & Celgene & \\
		Opdivo & Bristol-Myers Squibb Ono Pharmaceutical & \\
		Imbruvica & AbbVie (Pharmacyclics) Johnson and Johnson & \\
		Keytruda & Merck and Company & \\
		Ibrance & Pfizer & \\
		Tecentriq & Roche & \\
		Darzalex & Johnson and Johnson & \\
		Perjeta & Roche & \\
		Xtandi & Astellas Pharma and Pfizer & \\
		Avastin & Roche & \\
		Herceptin & Roche & \\
		Gazyva & Roche & \\
		Jakafi & Novartis & \\
		Venclexta & Roche & \\
		Rituxan & Roche, Pharmstandard & \\
		\hline
	\end{tabular}
\end{table}

\section{Materials and Methods}

\begin{enumerate}
	\item METHOD INVENT systems NOT components of systems. \cite{key1000}
	\item SELECT PROBLEM domain in KNOWLEDGE Space.\cite{key1000}
	\item INVENTED ECONOMIC system of lighting. \cite{key1000}
	\item INVENT by REPETITION with ADAPTATION to complex environments by INCREMENTAL SMALL CHANGE to APPROXIMATE final USE.\cite{key1000}
	\item BLENDED Economics with INVENT. \cite{key1000}
	\item ASSEMBLED and ORGANIZED the RESOURCES. \cite{key1000}
	\item EFFECTIVE DRAWING. \cite{key1000}
	\item ABILITY ADAPT to COMPLEX change. \cite{key1000}
	\item METAPHOR to INVENT. \cite{key1000}
	\item INVENTION, ENGINEERING and MANUFACTURING are Different. \cite{key1000}
\end{enumerate}

\begin{enumerate}
	\item Value-at-Risk (VaR) is CLASSICAL DOWNSIDE risk MEASURE.\cite{key100}
	\item RETURNS are Data TRANSFORMATIONS. \cite{key100}
	\item IF RETURNS with SKEWNESS AND OR EXCESS KURTOSIS, then Cornish-Fisher MEASURES. \cite{key100}
	\item VaR DECOMPOSITIONS total portfolio VaR into risk PERCENTAGE of EACH portfolio COMPONENT. \cite{key100}
	\item Value-at-Risk (VaR) for (a) univariate, (b) component, (c) marginal cases by DIFFERENT METHODS. \cite{key100}
	\item Expected Shortfall (ES) OR Conditional Value at Risk (CVaR) OR Expected Tail Loss (ETL) for (a) univariate, (b) component (c) marginal cases by DIFFERENT METHODS. \cite{key100}
	\item DEFAULT probability level INTERVAL 1 < a < 5 percent, ES of RETURNS is negative VALUE of expected VALUE of RETURN when RETURN less a-quantile.  \cite{key100}
	\item Conditional value-at-risk (CVaR) is risk MEASURE COHERENT AND CONVEX function of portfolio WEIGHTS. \cite{key100}
\end{enumerate}


\begin{table}[ht]
	\caption{Symbol Movement Indicator \cite{key100}}
	\begin{tabular}{rlll}
		\hline
		ID & Indicator & Stock Symbol A & Comment \\
		\hline
		101 & Monthly Downside Risk & 0 & \\ 
		102 & Annualised Downside Risk & 0 & \\ 
		103 & Downside Potential & 0 & \\ 
		104 & Upside Potential & 0 & \\ 
		105 & Upside Potential ratio & 0 & \\ 
		200 & Omega & 0 &  \\ 
		300 & Sortino ratio & 0 & \\ 
		400 & Omega-sharpe ratio & 0 & \\ 
		\hline
	\end{tabular}
\end{table}


\section{References}

\subsection{Methodology}

\bibitem[1]{key1000}Wikipedia contributors. (2017, September 12). 
\newblock Edisonian approach. 
\newblock In Wikipedia, The Free Encyclopedia. Retrieved August 3, 2018, from  https://en.wikipedia.org/w/index.php?title=Edisonian_approach&oldid=800292477

\subsection{Combinatorial Chemistry}

\bibitem[1]{key500}Richard Pommier Swanson (2004)
\newblock The Entrance of Informatics into Combinatorial Chemistry
\newblock American Society for Information Science and Technology


\subsection{Immuno-Oncology}

\bibitem[2]{key8001}Special Report (2017)
\newblock Top 15 Best Selling Cancer Drugs 2022
\newblock Retrieved July 31, 2018, from https://www.fiercepharma.com/special-report/special-report-top-15-best-selling-cancer-drugs-2022

\subsection{Econometrics}

\bibitem[3]{key400} Christian Garavaglia, Franco Malerba, Luigi Orsenigo, Michele Pezzoni (2014)
\newblock Innovation and Market Structure in Pharmaceuticals An Econometric Analysis on Simulated Data
\newblock Jahrbücher für Nationalökonomie und Statistik 

\subsection{R API}

\bibitem[1]{key100} Brian G. Peterson and Peter Carl (2018). 
\newblock PerformanceAnalytics:Econometric Tools for Performance and Risk Analysis. 
\newblock R package version 1.5.2.https://CRAN.R-project.org/package=PerformanceAnalytics

\bibitem[1]{key101}Csardi G, Nepusz T: 
\newblock The igraph software package for complex network research,
\newblock InterJournal, Complex Systems 1695. 2006. http://igraph.org

\bibitem[1]{key102}Douglas Bates and Martin Maechler (2017). 
\newblock Matrix: Sparse and Dense Matrix Classes and Methods. 
\newblock R package version 1.2-11. https://CRAN.R-project.org/package=Matrix

\bibitem[1]{key103}David B. Dahl (2016). 
\newblock xtable: Export Tables to LaTeX or HTML. 
\newblock R package version 1.8-2. https://CRAN.R-project.org/package=xtable

\bibitem[1]{key104}Hyndman RJ (2017). 
\newblock forecast: Forecasting functions for time series and linear models. 
\newblock R package version 8.1, <URL:http://github.com/robjhyndman/forecast>.

\bibitem[1]{key105}Hyndman RJ and Khandakar Y (2008).
\newblock Automatic time series forecasting: the forecast package for R.” 
\newblock Journal of Statistical Software_, *26*(3), pp. 1-22.

\bibitem[1]{key106}David Shaub and Peter Ellis (2017).
\newblock forecastHybrid: Convenient Functions for Ensemble Time Series Forecasts. 
\newblock R package version 1.1.9. https://CRAN.R-project.org/package=forecastHybrid

\bibitem[1]{key107}Raviv E (2015). 
\newblock ForecastCombinations:Forecast combinations in R. 
\newblock R package version 1.1, <URL:https://CRAN.R-project.org/package=ForecastCombinations>.

